Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GMED Stock Forecast 2026-2027
$93.83
Current Price
$12.69B
Market Cap
Buy 10
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to GMED Price Targets
+31.1%
To High Target of $123.00
+22.0%
To Median Target of $114.50
-4.1%
To Low Target of $90.00
GMED Price Momentum
-0.8%
1 Week Change
+8.8%
1 Month Change
+33.9%
1 Year Change
+7.5%
Year-to-Date Change
-7.5%
From 52W High of $101.40
+81.2%
From 52W Low of $51.79
📊 TOP ANALYST CALLS
Did GMED Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Globus Medical is one of their latest high-conviction picks.
Latest GMED Stock Price Targets & Analyst Predictions
Based on our analysis of 24 Wall Street analysts, GMED has a bullish consensus with a median price target of $114.50 (ranging from $90.00 to $123.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $93.83, the median forecast implies a 22.0% upside. This outlook is supported by 10 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matt Miksic at Barclays, projecting a 31.1% upside. Conversely, the most conservative target is provided by William Plovanic at Canaccord Genuity, suggesting a 4.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GMED Analyst Ratings
10
Buy
4
Hold
0
Sell
GMED Price Target Range
Low
$90.00
Average
$114.50
High
$123.00
Current: $93.83
Latest GMED Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GMED.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 26, 2026 | Wells Fargo | Vik Chopra | Overweight | Maintains | $104.00 |
| Feb 25, 2026 | Needham | David Saxon | Buy | Maintains | $114.00 |
| Feb 25, 2026 | Barclays | Matt Miksic | Overweight | Maintains | $123.00 |
| Jan 30, 2026 | Needham | David Saxon | Buy | Upgrade | $112.00 |
| Jan 9, 2026 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $112.00 |
| Jan 8, 2026 | Piper Sandler | Matt O'Brien | Overweight | Reiterates | $115.00 |
| Dec 17, 2025 | RBC Capital | Shagun Singh | Outperform | Maintains | $100.00 |
| Dec 17, 2025 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $105.00 |
| Dec 17, 2025 | Freedom Capital Markets | Keith Hinton | Hold | Initiates | $87.00 |
| Dec 2, 2025 | Morgan Stanley | Drew Ranieri | Overweight | Maintains | $100.00 |
| Nov 18, 2025 | Truist Securities | Richard Newitter | Buy | Reiterates | $105.00 |
| Nov 10, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $114.00 |
| Nov 7, 2025 | Truist Securities | Richard Newitter | Buy | Upgrade | $93.00 |
| Nov 7, 2025 | RBC Capital | Shagun Singh | Outperform | Maintains | $92.00 |
| Nov 7, 2025 | Wells Fargo | Vik Chopra | Overweight | Maintains | $79.00 |
| Nov 7, 2025 | B of A Securities | Craig Bijou | Buy | Upgrade | $91.00 |
| Oct 28, 2025 | Stifel | Thomas Stephan | Hold | Reinstates | $64.00 |
| Oct 10, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Aug 8, 2025 | Wells Fargo | Vik Chopra | Overweight | Maintains | $66.00 |
| Jul 22, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $90.00 |
Globus Medical Inc. (GMED) Competitors
The following stocks are similar to Globus Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GMED
Globus Medical
mkt cap
12.88B
Globus Medical Inc. (GMED) Financial Data
Globus Medical Inc. has a market capitalization of $12.69B with a P/E ratio of 24.3x. The company generates $2.94B in trailing twelve-month revenue with a 18.3% profit margin.
Revenue growth is +25.7% quarter-over-quarter, while maintaining an operating margin of +24.4% and return on equity of +12.3%.
Valuation Metrics
Market Cap
$12.69B
Enterprise Value
$12.45B
P/E Ratio
24.3x
PEG Ratio
0.1x
Price/Sales
4.4x
Growth & Margins
Revenue Growth (YoY)
+25.7%
Gross Margin
+68.4%
Operating Margin
+24.4%
Net Margin
+18.3%
EPS Growth
+430.4%
Financial Health
Cash/Price Ratio
+4.4%
Current Ratio
4.3x
Debt/Equity
2.6x
ROE
+12.3%
ROA
+7.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Globus Medical Inc. (GMED) Business Model
About Globus Medical Inc.
What They Do
Develops innovative musculoskeletal implantable devices.
Business Model
The company generates revenue by designing, manufacturing, and selling implantable devices and surgical instruments for various medical procedures, including spinal and orthopedic surgeries. It leverages its strong research and development capabilities to create advanced technologies and provides education and clinical support to healthcare professionals to enhance surgical outcomes.
Additional Information
Founded in 2003 and headquartered in Audubon, Pennsylvania, the company focuses on addressing unmet clinical needs through innovation in its product offerings. It emphasizes collaboration with surgeons for product development and continuous improvement, positioning itself as a leader in the medical device industry.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
5,300
CEO
Mr. Keith W. Pfeil
Country
United States
IPO Year
2012
Website
www.globusmedical.comGlobus Medical Inc. (GMED) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
UnitedHealth Q1 Earnings Beat Estimates on Rising Premiums
UNH tops Q1 EPS on strong commercial fee-based membership and Optum Rx despite Optum Health weakness and declining risk-based membership.
Apr 21, 2026
By Zacks Equity Research
Analyst Blog
Should You Continue to Hold Resmed Stock in Your Portfolio?
RMD's growth strategy, rising device demand and solid finances support momentum, but macro pressures and stiff competition could test its outlook.
Apr 17, 2026
By Zacks Equity Research
Analyst Blog
Abbott Stock Falls Despite Q1 Earnings & Revenue Beat
ABT slips 4% despite Q1 beats as margin pressure, Nutrition weakness and lowered 2026 EPS guidance weigh on investor sentiment.
Apr 16, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Globus Medical (NYSE:GMED) will report Q1 2026 financial results on May 7, 2026, after market close. The release will be available on their investor website.
Why It Matters
Globus Medical's upcoming financial results could influence stock performance, investor sentiment, and market expectations for growth in the musculoskeletal technology sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Zacks Premium offers Style Scores to help investors identify strong stocks across value, growth, and momentum strategies.
Why It Matters
Zacks Style Scores enhance stock selection for various investment strategies, potentially leading to better returns and informed decision-making for investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Robotics stocks such as GMED, ADSK, MCHP, and ROK are experiencing growth due to advancements in physical AI, automation, and medical robotics, projected to boost the industry in 2026.
Why It Matters
Rising momentum in robotics stocks signals strong future growth potential, driven by advancements in AI and automation, which can enhance investment returns in the sector.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Globus Medical (GMED) has been upgraded to a Zacks Rank #1 (Strong Buy) due to increasing optimism about its earnings prospects.
Why It Matters
Globus Medical's upgrade to Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and driving stock prices higher.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
GMED benefits from NuVasive synergies, strong cash flow, and rapid innovation; however, macroeconomic pressures and rising costs may impact its near-term outlook.
Why It Matters
GMED's reliance on NuVasive synergies and strong cash flow indicates growth potential, but macroeconomic pressures and rising costs may impact profitability and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
New Strong Buy Stocks for April 8th
14 days ago
Quick Summary
BE, SM, KRUS, GMED, and BP have been assigned a Zacks Rank #1 (Strong Buy) as of April 8, 2026.
Why It Matters
The addition of BE, SM, KRUS, GMED, and BP to the Zacks Rank #1 (Strong Buy) List signals strong growth potential, attracting investor interest and potentially boosting stock prices.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About GMED Stock
What is Globus Medical Inc.'s (GMED) stock forecast for 2026?
Based on our analysis of 24 Wall Street analysts, Globus Medical Inc. (GMED) has a median price target of $114.50. The highest price target is $123.00 and the lowest is $90.00.
Is GMED stock a good investment in 2026?
According to current analyst ratings, GMED has 10 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $93.83. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GMED stock?
Wall Street analysts predict GMED stock could reach $114.50 in the next 12 months. This represents a 22.0% increase from the current price of $93.83. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Globus Medical Inc.'s business model?
The company generates revenue by designing, manufacturing, and selling implantable devices and surgical instruments for various medical procedures, including spinal and orthopedic surgeries. It leverages its strong research and development capabilities to create advanced technologies and provides education and clinical support to healthcare professionals to enhance surgical outcomes.
What is the highest forecasted price for GMED Globus Medical Inc.?
The highest price target for GMED is $123.00 from Matt Miksic at Barclays, which represents a 31.1% increase from the current price of $93.83.
What is the lowest forecasted price for GMED Globus Medical Inc.?
The lowest price target for GMED is $90.00 from William Plovanic at Canaccord Genuity, which represents a -4.1% decrease from the current price of $93.83.
What is the overall GMED consensus from analysts for Globus Medical Inc.?
The overall analyst consensus for GMED is bullish. Out of 24 Wall Street analysts, 10 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $114.50.
How accurate are GMED stock price projections?
Stock price projections, including those for Globus Medical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 9:18 AM UTC